Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients.
Antiemetic activity of three protracted regimens for the control of cisplatin-evoked delayed emesis was explored. 63 patients were randomly assigned to receive one of three protracted antiemetic schedules over 4 days. Group C patients received dexamethasone 8 mg twice daily on days 2 and 3, then 4 mg twice daily on days 4 and 5; in group B, alizapride 2.5 mg/kg four times daily on days 2-5 plus dexamethasone as in group C was administered; and in group A, metoclopramide 0.5 mg/kg four times daily on days 2-5 plus dexamethasone was given at the same dose-schedule as in groups C and B. Complete protection from delayed vomiting was achieved in 44% of group C, 30% of B and 70% of group A (P = 0.02). Mild side-effects were noted in all three groups. A higher complete protection for delayed emesis was obtained in metoclopramide-dexamethasone-treated patients. Neither of the regimens used in the protection of delayed emesis controlled late nausea.
Moreno
I
I
Medical Oncology Unit, Hospital Terrasa, Barcelona, Spain.
Rosell
R
R
Abad
A
A
Barnadas
A
A
Carles
J
J
Ribelles
N
N
Solano
V
V
Font
A
A
D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects*; D003907:Dexamethasone / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000627:therapeutic use; D008875:Middle Aged; D011759:Pyrrolidines / Q000627:therapeutic use; D016037:Single-Blind Method; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced*
D000932:Antiemetics; D011759:Pyrrolidines; D003907:Dexamethasone; D008787:Metoclopramide; C033968:alizapride; D002945:Cisplatin